LIDDS

0.052

SEK

+36.84 %

Less than 1K followers

LIDDS

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+36.84%

-56.3%

-58.57%

-48.77%

-48%

-68.48%

-99.07%

-99.66%

-99.46%

LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patent-protected and clinically tested drug delivery technology. The properties of the products form the basis of LIDDS 'technology platform for the development of injectable drug products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System and the company is headquartered in Uppsala.

Market cap

7.1M SEK

Turnover

4.06K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Financial calendar

29.5

2025

Interim report Q1'25

29.5

2025

General meeting '25

28.8

2025

Interim report Q2'25

All

Press releases

ShowingAll content types

Regulatory press release4/10/2025, 11:30 AM

LIDDS has decided to write-down intangible assets

Regulatory press release4/2/2025, 1:00 PM

LIDDS has decided to cease further development

Regulatory press release2/20/2025, 7:00 AM

LIDDS AB (publ) Year-end Report 2024

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release12/3/2024, 9:00 AM

Nomination Committee appointed for the Annual General Meeting 2025 in LIDDS

Regulatory press release11/21/2024, 7:00 AM

LIDDS AB (publ) Interim Report January – September 2024

Press release9/26/2024, 3:00 PM

LIDDS has decided to concentrate its activities on three project areas

Regulatory press release8/28/2024, 8:00 AM

LIDDS AB (publ) Interim Report January – June 2024

Regulatory press release5/30/2024, 7:00 AM

LIDDS AB (publ) Interim Report January – March 2024

Regulatory press release5/27/2024, 9:50 AM

Bulletin from the Annual General Meeting in LIDDS AB (PUBL) on 27 May 2024

Regulatory press release5/26/2024, 9:20 PM

LIDDS moves the publication of the Interim Report for the first quarter 2024

Regulatory press release5/14/2024, 3:10 PM

LIDDS appoints Mats Wiking as new CEO

Regulatory press release5/6/2024, 1:05 PM

LIDDS’ Annual Report 2023 published

Regulatory press release4/26/2024, 6:30 AM

NOTICE OF THE ANNUAL GENERAL MEETING IN LIDDS AB (publ)

Regulatory press release4/17/2024, 9:50 AM

LIDDS moves the publication of the Annual Report 2023 forward

Press release3/21/2024, 11:05 AM

LIDDS has concluded the acquisition of Noviga

Regulatory press release2/27/2024, 10:35 AM

Bulletin from the Extraordinary General Meeting in LIDDS AB (PUBL) on 27 February 2024

Regulatory press release2/22/2024, 8:30 AM

LIDDS AB (publ) Year-end Report 2023

Regulatory press release1/29/2024, 7:40 AM

NOTICE OF THE EXTRAORDINARY GENERAL MEETING IN LIDDS AB (publ)

Regulatory press release1/29/2024, 7:35 AM

LIDDS acquires Noviga Research

Regulatory press release1/9/2024, 12:10 PM

Bulletin from the Extraordinary General Meeting in LIDDS AB (PUBL) on 9 January 2024

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.